Developing Better Drugs to Slow the
Progression of MS
Lab testing shows the dramatic suppression of paralysis using a novel molecular treatment strategy.
Vulcan Bioscience's unique approach to drug development can help to improve the lives of those with Relapse Remitting Multiple Sclerosis (RRMS), which affects 85% of those struggling with the disease.
Vulcan Biosciences Expands Leadership Team And Strengthens Drug Development Capabilities
Birmingham, AL, February 12th 2020 – Vulcan Biosciences, Inc. announced today the hiring of Omar Flores, Ph.D., M.B.A., as Chief Executive Officer. Dr. Flores has prior experience taking early s...read more
Multiple Sclerosis Drug Discovery Program Yields Two Novel Drugs With Clinical Efficacy In The EAE Mouse Model
Birmingham, AL, December 9th 2019 – The results obtained from an unbiased and thorough analysis of potential drug targets in multiple sclerosis has been successful, culminating in the identification o...read more
Vulcan Biosciences Closes A Seed Investment Round To Identify New Drugs For Multiple Sclerosis
Birmingham, AL, August 1st 2019 – Vulcan Biosciences, Inc. a biotechnology company focused on finding more effective treatments for patients with multiple sclerosis, announced today that it has secure...read more